Trial Profile
A Randomized, Open Label, Multicenter Phase 2 Study, to Evaluate the Efficacy of Sorafenib in Patients With Advanced Renal Cell Carcinoma (RCC) After a Radical Resection of the Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms RESORT
- 08 Sep 2022 This trial was completed in Italy, according to European Clinical Trials Database.
- 16 Sep 2021 Planned End Date changed from 1 Sep 2019 to 1 Mar 2022.
- 16 Sep 2021 Status changed from completed to active, no longer recruiting.